tickrz reports
Thermo Fisher Scientific Inc (TMO)
Healthcare | Health Services
208  -1.03%
TMO vs HEALTH SERVICES SECTOR & S&P 500
VALUATION
TMOSECTORS&P 500
P/E RATIO38.1532.921.12
EV/EBITDA RATIO25.3718.312.66
P/S RATIO4.423.92.25
P/B RATIO3.85.83.45
QUALITY
RETURN ON EQUITY10.16%14.19%13.64%
RETURN ON CAPITAL7.2%20.57%10.09%
NET MARGIN11.08%8.82%9.73%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0.29%
PAYOUT RATIO10.93%
3 YR DIVIDEND GROWTH0%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY78%
INTEREST COVERAGE5.6x
CURRENT RATIO1.37
GROWTH
5 YR EPS GROWTH13.82%
5 YR SPS GROWTH9.59%
5 YR BPS GROWTH6.22%
About tickrz
Key Concepts
Great Investors
Thermo Fisher Scientific Inc 's strong growth translates to a Growth Rank in the top 25% of all stocks
TICKRZBOT SUMMARY
Thermo Fisher Scientific Inc receives a C ranking in our multi-factor model that blends valuation, moat, operational performance, and financial strength. View the tickrz MFM Screener here. Here's a summary of Thermo Fisher Scientific Inc's factor rankings that are combined together to calculate the tickrz MFM ranking:

FACTOR RANKINGSFACTOR SCREENER 
TICKRZ MFM RANK C / 283PURE VALUE RANKD / 396
DIVIDEND RANKA / 13MOAT RANKA / 73
FINANCIAL STRENGTH RANKB / 113GROWTH RANKA / 101
MOMENTUM RANKB / 125
GURU ANALYSIS
Buffett Rank B / 213Peter Lynch Rank C / 231
Thermo Fisher Scientific Inc ranks 213 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. The stock's average Buffett rank suggests waiting for improved valuation or quality metrics before taking action. The company's moat is strong so it could be worth investigating in the future should its valuation improve.Our Peter Lynch mutli-factor model ranks stocks on their PEG ratio, Financial Strength, margin profile, and their P/Es relative to their respective industry groups. Thermo Fisher Scientific Inc ranks 231, a relatively weak ranking.
Alex Roepers Rank C / 285Joel Greenblatt Rank D / 402
Alex Roepers, founder of Atlantic Investment Management, looks for stocks trading at low EV/EBITDA multiples with strong and consistent free cash flow. Thermo Fisher Scientific Inc ranks 285 out of the S&P 500 constituents on our Roepers-inspired multi-factor model.In his best-selling The Little Book that Beats the Market, Greenblatt introduced the Magic Formula, a straightforward approach that ranks stocks on earnings yield and return on invested capital. Thermo Fisher Scientific Inc places 402 out the S&P 500 consitituents on this ranking methodology.
FACTOR RANKINGS
Value
Pure Value Ranking D / 396
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Thermo Fisher Scientific Inc's valuation score is comprised of a P/E ratio of 38.2x, a P/B ratio of 3.8x, a P/S ratio of 4.4x, and an EV/EBITDA ratio of 25.4x. Thermo Fisher Scientific Inc ranks 396 out of the S&P 500 constituents on valuation--a relatively weak score.

Quality
Moat A / 73Financial Strength B / 113
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Thermo Fisher Scientific Inc appears to have a durable competitive advantage within the Healthcare sector. Thermo Fisher Scientific Inc has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.6x, a debt/equity ratio of 78% and a Moat Rank of 73 translate to an average Financial Strength score.


Momentum B / 125
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 29.81% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 125. Based on its 12 month stock performance, Thermo Fisher Scientific Inc will not appeal to momentum investors.

Yield A / 13
Value + Yield
Shares currently yield 0.29%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Thermo Fisher Scientific Inc ranks 13 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate Thermo Fisher Scientific Inc.

Growth A / 101
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 13.8% 5 year annualized EPS growth, 9.6% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 6.2% speak to its impressive growth ranking.

Thermo Fisher Scientific Inc (TMO)
Healthcare | Health Services
208  -1.03%


tickrz rank
C
VALUATION RATIOS
P/E Ratio38.15x
P/B Ratio3.8x
P/S Ratio4.42x
EV/EBITDA Ratio25.37x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0.29%
PAYOUT RATIO10.93%
3 YR DIVIDEND GROWTH0%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY78%
INTEREST COVERAGE5.6x
CURRENT RATIO1.37
MOAT
ROE10.16%
ROIC7.2%
Net Margin11.08%
GROWTH
5 YR EPS GROWTH13.82%
5 YR SPS GROWTH9.59%
5 YR BPS GROWTH6.22%

TICKRZ RANK
Thermo Fisher Scientific Inc receives a C ranking in our multi-factor model that blends valuation, moat, operational performance, and financial strength. View the tickrz MFM Screener here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Thermo Fisher Scientific Inc's valuation score is comprised of a P/E ratio of 38.2x, a P/B ratio of 3.8x, a P/S ratio of 4.4x, and an EV/EBITDA ratio of 25.4x. Thermo Fisher Scientific Inc ranks 396 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Thermo Fisher Scientific Inc ranks 213 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. The stock's average Buffett rank suggests waiting for improved valuation or quality metrics before taking action. The company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Thermo Fisher Scientific Inc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Thermo Fisher Scientific Inc has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.6x, a debt/equity ratio of 78% and a Moat Rank of 73 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 29.81% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 125. Based on its 12 month stock performance, Thermo Fisher Scientific Inc will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 0.29%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Thermo Fisher Scientific Inc ranks 13 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate Thermo Fisher Scientific Inc.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 13.8% 5 year annualized EPS growth, 9.6% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 6.2% speak to its impressive growth ranking.